bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
5.06
-0.03 (-0.67%)
Aug 27, 2026, 1:27 PM EDT - Market open

bioAffinity Technologies Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
5.96.169.362.530-
Revenue Growth
-23.18%-34.18%269.68%52627.44%--
Gross Profit
2.041.943.380.790-
Operating Income
-12.38-10.57-8.95-7.97-4.01-2.21
Net Income
-15.19-14.91-9.04-7.94-8.15-6.33
Earnings Per Share
-59.70-129.94-335.50-408.30--
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Diagnostic R&D
-00.010.02-
Laboratory Services
5.96.169.352.510
Total
5.96.169.362.530

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2.436.451.112.8211.411.36
Total Debt
1.441.161.51.580.2511.36
Net Cash (Debt)
0.995.29-0.41.2411.16-10
Net Cash Growth
648.82%---88.87%--
Net Cash Per Share
3.9146.10-14.6963.94--

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-11.47-9.33-7.26-6.04-4.07-2.05
Capital Expenditures
-0.09-0.06-0.08-0.02-0.22-
Free Cash Flow
-11.56-9.39-7.34-6.06-4.29-2.05
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
34.61%31.41%36.09%31.26%90.28%-
Operating Margin
-209.82%-171.58%-95.64%-314.84%-83511.51%-
Pretax Margin
-257.23%-241.25%-96.43%-312.58%-169720.05%-
Profit Margin
-257.33%-241.96%-96.56%-313.41%-169771.25%-
FCF Margin
-195.90%-152.38%-78.44%-239.32%-89336.50%-

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.470.861.525.522788.11-